arrow
C

Choon Kiat Ong

Duke-NUS Medical School
H指数:62
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acquired resistance to vorinostat in cutaneous T cell lymphoma involves augmented ERK phosphorylation

获得性耐药性导致皮肤T细胞淋巴瘤对vorinostat产生耐药,涉及增强的ERK磷酸化

2026-11-050
OAAI
Multimodal spatial profiling reveals distinct myeloid-defined ENKTL subgroups and tumor-myeloid cooperativity within prognostic inflammatory niche

多模态空间分析揭示髓系定义的ENKTL亚组及其在预后炎性微环境中的肿瘤-髓系协同作用

Leukemia
IF13.4
2026-08-240
OAAI
Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer

甲羟戊酸通路的重编程由增强子重塑驱动,赋予结直肠癌对KRAS抑制剂的耐药性

2026-06-020
OAAI
Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma

CD38和PD-1联合抑制(使用isatuximab和cemiplimab)对复发/难治性NK/T细胞淋巴瘤的疗效

Blood
IF23.1
2025-03-130
PRE
Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma- Potential Synergy with Immune Checkpoint Blockade

非霍奇金淋巴瘤中布马那韦的治疗重定位——与免疫检查点阻断的潜在协同作用

BLOOD
IF23.1
2024-11-050
PRE
Comprehensive molecular characterization of collecting duct carcinoma for therapeutic vulnerability

集合管癌治疗易损性的综合分子表征

2024-08-090
PRE
CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma

CDK4/6抑制增强XPO1抑制剂selinexor在自然杀伤/T细胞淋巴瘤中的抗肿瘤功效

2024-08-010
OA
Transcriptomic convergence despite genomic divergence drive field cancerization in synchronous squamous tumors

转录组学收敛尽管在同步鳞状肿瘤中基因组差异驱动场癌变

2024-06-130
OAAI
4EBP1-mediated SLC7A11 protein synthesis restrains ferroptosis triggered by MEK inhibitors in advanced ovarian cancer

4ebp1介导的SLC7A11蛋白合成抑制MEK抑制剂在晚期卵巢癌中引发的铁死亡

2024-06-061
OAAI
Targeting AURKA to induce synthetic lethality in CREBBP-deficient B-cell malignancies via attenuation of MYC expression

靶向AURKA通过减弱MYC表达诱导CREBBP缺陷的b细胞恶性肿瘤的合成致死率

2024-05-230
PRE
Potent anti-proliferative activity of brincidofovir in Diffuse Large B-cell Lymphoma with overexpression of transcriptional repressor TLE1
2024-03-220
PRE
The Atlas of Blood Cancer Genomes: A resource for therapeutic and biomarker development
2024-03-220
PRE